Overall Severe Morbidity After Chemo-Radiation Therapy and Magnetic Resonance Imaging-Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study

Vittrup, Anders Schwartz; Kirchheiner, Kathrin; Pötter, Richard; Fokdal, Lars; Jensen, Nina Boje Kibsgaard; Spampinato, S.; Haie-Méder, Christine; Schmid, Maximilian; Sturdza, Alina; Mahantshetty, Umesh; Hoskin, Peter; Šegedin, Barbara; Bruheim, Kjersti; Rai, Bhavana; Wiebe, Ericka; Steen-Banasik, Elzbieta van der; Cooper, R.; Limbergen, Erik; Sundset, Marit; Pieters, Bradley R.; Kirisits, Christian; Lindegaard, Jacob Christian; Jürgenliemk-Schulz, Ina M.; Nout, Remi A.; Tanderup, Kari

doi:10.1016/j.ijrobp.2023.01.002

Cited by 10 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we believe that the key to reducing radiation exposure to the bladder and rectum lies in the sophisticated delivery of brachytherapy doses through the use of a gel spacer. According to the findings reported by Vittrup et al, based on the long-term late severe toxicity analysis from the EMBRACE-I study [28] , it is advised that the total dose of pelvic external beam radiation therapy (EBRT) should be 45 Gy, rather than 50 Gy. This lower pelvic EBRT dose recommendation aims to reduce the risk of late severe gastrointestinal toxicities, such as late diarrhea and pelvic bone fractures.…”

Section: Discussionmentioning

confidence: 99%

MucoUp® as a spacer in brachytherapy for uterine cervical cancer: A first-in-human experience

Muramoto

Murakami

Karino

et al. 2023

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

MucoUp® as a spacer in brachytherapy for uterine cervical cancer: A first-in-human experience

Muramoto

Murakami

Karino

et al. 2023

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

“…Common treatment options for patients with cervical cancer include surgery if diagnosed in its early stages [ 10 , 11 , 12 ]. Radiation therapy and chemotherapy, separately or in combination, are used for patients with advanced stages of cervical cancer [ 13 , 14 , 15 , 16 ]. External beam and internally delivered radiation (brachytherapy) are often used in the radiotherapy of cervical cancer [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment

Moreau,

Keno,

China

et al. 2024

Cancers

View full text Add to dashboard Cite

Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) imaging visibility were also evaluated in human cadavers. A pharmacodynamics study was also conducted to assess the safety of LIFE Biomaterial in healthy C57BL6 female mice. Results showed that LIFE Biomaterial could provide both CT and MR imaging contrast over time. Inhibition in tumor growth and prolonged significant survival (* p < 0.05) were consistently observed for groups treated with the combination of radiotherapy and LIFE Biomaterial, highlighting the potential for this strategy. Minimal toxicity was observed for healthy mice treated with LIFE Biomaterial with/without anti-CD40 in comparison to non-treated cohorts. The results demonstrate promise for the further development and clinical translation of this approach to enhance the survival and quality of life of patients with advanced cervical cancer.

show abstract

Let’s talk about sex: consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology: clinical recommendations after pelvic radiotherapy

Gil Haro,

Cordoba Largo,

Rodriguez Rodriguez

et al. 2024

Clin Transl Oncol

View full text Add to dashboard Cite

Overall Severe Morbidity After Chemo-Radiation Therapy and Magnetic Resonance Imaging-Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study

Cited by 10 publications

References 48 publications

MucoUp® as a spacer in brachytherapy for uterine cervical cancer: A first-in-human experience

MucoUp® as a spacer in brachytherapy for uterine cervical cancer: A first-in-human experience

Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment

Let’s talk about sex: consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology: clinical recommendations after pelvic radiotherapy

Contact Info

Product

Resources

About